Yeqin Sha
YOU?
Author Swipe
View article: Identification of Gαi1 as a key regulator of tumor progression in nasopharyngeal carcinoma
Identification of Gαi1 as a key regulator of tumor progression in nasopharyngeal carcinoma Open
Gαi1 promotes tumor progression in NPC through the cell cycle, ERK and Akt-mTOR pathway and by regulating SETD7. Targeting Gαi1 or its signaling may offer a novel therapeutic strategy for NPC and potentially other cancers.
View article: Graft-versus-HIV-reservoir reactivity: Long term HIV remission after allogeneic stem cell transplantation from a donor with active CCR5
Graft-versus-HIV-reservoir reactivity: Long term HIV remission after allogeneic stem cell transplantation from a donor with active CCR5 Open
Background HIV cure is exceptionally rare and is documented in only six cases. All HIV cure cases were individuals receiving allogeneic stem cell transplantations (alloSCT) from donors with rare homozygous CCR5 Δ32 receptor mutation, that …
View article: Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non–germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG)
Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non–germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG) Open
View article: Prognostic impacts of marital status and other socioeconomic factors in patients with chronic lymphocytic leukemia: an analysis of SEER database
Prognostic impacts of marital status and other socioeconomic factors in patients with chronic lymphocytic leukemia: an analysis of SEER database Open
Background: Marital status has been demonstrated to impact the outcomes of several malignancies. The prognostic role of marital status in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has not been determined. Methods: W…
View article: 529 | DIAGNOSTIC AND PROGNOSTIC IMPACTS OF RHOA G17V MUTATION IN CELL‐FREE DNA ASSESSED BY ddPCR IN PATIENTS WITH AITL
529 | DIAGNOSTIC AND PROGNOSTIC IMPACTS OF RHOA G17V MUTATION IN CELL‐FREE DNA ASSESSED BY ddPCR IN PATIENTS WITH AITL Open
View article: 550 | PHASE II TRIAL OF ORELABRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA: THE CWCLL‐001 TRIAL
550 | PHASE II TRIAL OF ORELABRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA: THE CWCLL‐001 TRIAL Open
View article: 176 | EGR2 MUTATIONS CONFER POOR PROGNOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH BRUTON TYROSINE KINASE INHIBITORS
176 | EGR2 MUTATIONS CONFER POOR PROGNOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH BRUTON TYROSINE KINASE INHIBITORS Open
View article: Prognostic impacts of <i>RHOA G17V</i> mutation in cell‐free <scp>DNA</scp> assessed by droplet digital polymerase chain reaction in patients with angioimmunoblastic T‐cell lymphoma
Prognostic impacts of <i>RHOA G17V</i> mutation in cell‐free <span>DNA</span> assessed by droplet digital polymerase chain reaction in patients with angioimmunoblastic T‐cell lymphoma Open
View article: A Qualitative Study on Cryptogenic Hepatic Encephalopathy Screening Cognition Among Hepatology Medical Care Personnel
A Qualitative Study on Cryptogenic Hepatic Encephalopathy Screening Cognition Among Hepatology Medical Care Personnel Open
Hepatology medical care personnel had a favorable outlook on CHE screening, however there is room for improvement in both their level of knowledge and clinical work. As a result the administrative departments of hospitals should focus on t…
View article: Exploring the Role of EBV Infection in EBV‐T/NKLPD With EBV Capture Technology Based on Single‐Cell RNA Sequencing
Exploring the Role of EBV Infection in EBV‐T/NKLPD With EBV Capture Technology Based on Single‐Cell RNA Sequencing Open
View article: Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience
Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience Open
View article: 加速期慢性淋巴细胞白血病患者的临床和分子生物学特征分析
加速期慢性淋巴细胞白血病患者的临床和分子生物学特征分析 Open
OBJECTIVE: To investigate the clinical and molecular biological characteristics of patients with accelerated chronic lymphocytic leukemia (aCLL). METHODS: From January 2020 to October 2022, the data of 13 patients diagnosed with aCLL at Th…
View article: Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort Open
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
View article: P592: SINGLE-CELL RNA SEQUENCING REVEALS THE SPATIAL HETEROGENEITY OF EXHAUSTED T CELLS IN BTKI-RESISTANT RICHTER TRANSFORMATION PATIENTS
P592: SINGLE-CELL RNA SEQUENCING REVEALS THE SPATIAL HETEROGENEITY OF EXHAUSTED T CELLS IN BTKI-RESISTANT RICHTER TRANSFORMATION PATIENTS Open
Topic: 5. Chronic lymphocytic leukemia and related disorders - Biology & Translational Research Background: The transformation of CLL to aggressive B-cell lymphoma (Richter transformation, RT) has remained a clinical challenge, with poor p…
View article: P607: INTEGRATING MULTI-OMICS TO REVEAL THE CLONAL EVOLUTIONARY CHARACTERISTICS IN CLL PATIENTS WITH ZANUBRUTINIB RESISTANCE
P607: INTEGRATING MULTI-OMICS TO REVEAL THE CLONAL EVOLUTIONARY CHARACTERISTICS IN CLL PATIENTS WITH ZANUBRUTINIB RESISTANCE Open
Background: The drug-resistant mechanisms of the first-generation Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has been extensively explored in Chronic Lymphocytic Leukemia (CLL) patients. However, the resistant mechanisms of the s…
View article: ZANUBRUTINIB PLUS BENDAMUSTINE AND CD20 MONOCLONAL ANTIBODY AS TREATMENT FOR MANTLE CELL LYMPHOMA
ZANUBRUTINIB PLUS BENDAMUSTINE AND CD20 MONOCLONAL ANTIBODY AS TREATMENT FOR MANTLE CELL LYMPHOMA Open
Introduction: To evaluate the safety and efficacy of Zanubrutinib Plus Bendamustine and CD20 monoclonal antibody As Treatment for Mantle Cell Lymphoma patients. Methods: We analyzed 15 MCL patients aged who received ZBR/G as treatment in o…
View article: Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment for chronic lymphocytic leukemia/ small lymphocytic leukemia: a single‐arm study
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment for chronic lymphocytic leukemia/ small lymphocytic leukemia: a single‐arm study Open
Introduction: BTK inhibitors (BTKi) monotherapy has introduced the concept of continuous treatment in CLL/SLL until disease progression, leading to several concerns like lack of deep remission, increasing risk of toxic effects and substant…
View article: RESEARCH ON COHORT OF PATIENTS RELAPSED ON BRUTON TYROSINE KINASE INHIBITORS (BTKI)
RESEARCH ON COHORT OF PATIENTS RELAPSED ON BRUTON TYROSINE KINASE INHIBITORS (BTKI) Open
Introduction: Acquired BTK/PLCG2 mutations remain to be the driver of drug resistance. The underlying mechanisms need to be further explored. In this study, we retrospectively analyzed the clinical and biological characteristics of fifty-f…
View article: Single‐cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi‐Resistant proliferative drive CLL patients
Single‐cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi‐Resistant proliferative drive CLL patients Open
Introduction: The underlying mechanisms of proliferative drive (PD) CLL including transformation of CLL to aggressive B-cell lymphoma (Richter transformation, RT) and accelerated CLL (aCLL) has not been fully disclosed yet, especially prog…
View article: Zanbrutinib, lenalidomide plus R‐CHOP (ZR2‐CHOP) as the first‐line treatment for non‐GCB diffuse large B‐cell lymphoma: An updated analysis of efficacy and tolerability
Zanbrutinib, lenalidomide plus R‐CHOP (ZR2‐CHOP) as the first‐line treatment for non‐GCB diffuse large B‐cell lymphoma: An updated analysis of efficacy and tolerability Open
Aims: To evaluate the safety and efficacy of zanubrutinib, lenalidomide plus R-CHOP (ZR2-CHOP) as the first-line treatment for non-GCB DLBCL patients, we updated the results in our cohort. Methods: We enrolled patients aged 18–75 with high…
View article: Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort Open
Time-limited treatment strategies in first line treatment of chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) were comprehensively explored. Thirty-four previously untreated, young fit CLL/SLL patients who initiated iFCR r…
View article: [Efficacy and safety of BTK inhibitor, venetoclax and rituximab in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma].
[Efficacy and safety of BTK inhibitor, venetoclax and rituximab in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma]. Open
View article: [Efficacy and safety of BTK inhibitor combined with bendamustine and rituximab in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma].
[Efficacy and safety of BTK inhibitor combined with bendamustine and rituximab in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma]. Open
View article: Clinical significance of prolymphocytes in Chinese patients with chronic lymphocytic leukemia including those treated with BTK inhibitors
Clinical significance of prolymphocytes in Chinese patients with chronic lymphocytic leukemia including those treated with BTK inhibitors Open
Background A higher percentage of prolymphocytes was reported to be associated with worse survival outcomes in patients with chronic lymphocytic leukemia (CLL). Therefore, we tried to explore the effect of prolymphocytes on the prognosis o…
View article: [Clonality relatedness and molecular characteristics of Richter transformation].
[Clonality relatedness and molecular characteristics of Richter transformation]. Open
Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliat…
View article: The pyroptosis-related gene signature predicts prognosis and indicates the immune microenvironment status of chronic lymphocytic leukemia
The pyroptosis-related gene signature predicts prognosis and indicates the immune microenvironment status of chronic lymphocytic leukemia Open
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world with great heterogeneity. Pyroptosis has recently been recognized as an inflammatory form of programmed cell death (PCD) and shares a close relationship wi…
View article: PB1860: CLONALITY RELATEDNESS AND MOLECULAR CHARACTERISTICS OF RICHTER SYNDROME
PB1860: CLONALITY RELATEDNESS AND MOLECULAR CHARACTERISTICS OF RICHTER SYNDROME Open
Background: Richter Syndrome (RS) is defined as the development of an aggressive lymphoma from chronic lymphocytic leukaemia/Small lymphocytic leukemia (CLL/SLL). RS clonally derived from CLL and RS unrelated to the original CLL display di…
View article: P625: SINGLE-CELL RNA SEQUENCING REVEALS THE HETEROGENEITY OF TUMOR CELLS AND IMMUNE MICROENVIRONMENT IN RICHTER SYNDROME AND ACCELERATED CLL
P625: SINGLE-CELL RNA SEQUENCING REVEALS THE HETEROGENEITY OF TUMOR CELLS AND IMMUNE MICROENVIRONMENT IN RICHTER SYNDROME AND ACCELERATED CLL Open
Background: Richter Syndrome (RS) is defined as development of aggressive lymphoma arising from chronic lymphocytic leukemia/Small lymphocytic leukemia (CLL/SLL). Accelerated CLL/SLL (aCLL/SLL) is pathologically defined as a highly prolife…
View article: [Monoclonal B-lymphocytosis complicated with chronic myelomonocytic leukemia and immune thrombocytopenia: a case report].
[Monoclonal B-lymphocytosis complicated with chronic myelomonocytic leukemia and immune thrombocytopenia: a case report]. Open
View article: [Comparison of four prognostic scoring system in patients with early asymptomatic chronic lymphocytic leukemia patients].
[Comparison of four prognostic scoring system in patients with early asymptomatic chronic lymphocytic leukemia patients]. Open
Objective: To compare the prognostic value of four prognostic models in predicting time to first treatment (TTFT) in patients with Binet A Chinese chronic lymphocytic leukemia (CLL) . Methods: This retrospective analysis incl…